Dopamine and Sensorimotor Function in Stuttering

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT07215884
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Stuttering, Adult

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • Aripiprazole 10 MG — DRUG
    The effects of aripiprazole on stuttering and various behavioral and neural outcomes will be studied compared to placebo.
  • Placebo — DRUG
    Placebo will be compared against aripiprazole for effect on stuttering and various behavioral and neural markers.

Study Details

This study is being done to understand the effect of aripiprazole on adults who stutter. Stuttering is a disorder that affects speech fluency. This study aims to understand sensorimotor pathways of stuttering and possible interventions.

Key Dates

Start date
Sep 30, 2025
Status verified
Oct 2025
Primary completion
Jun 30, 2026
Completion
Jun 30, 2026

Study Design

Enrollment
40 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE

Arms

  • Active Comparator: Single dose of aripiprazole
    Single dose of aripiprazole, 10mg administered orally. Participant and administrator will be blinded.
  • Placebo Comparator: Placebo dose
    A single placebo dose will be administered.

Primary Outcome Measure

Pre-speech auditory modulation [ Time Frame: 3-4 hours after intervention dose is delivered ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Biomagentic Imaging LabSan FranciscoCalifornia94143
Natalie Brunwin, MS
[email protected]
415-476-6888
John Houde, PhD (PRINCIPAL_INVESTIGATOR)
Srikantan Nagarajan, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in San Francisco, CA

By research site
Biomagentic Imaging Lab· San Francisco, CA

Related Studies